Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March 
Rio Tinto Posts Strong Q4 Iron Ore and Copper Output on Operational Recovery 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
Court Allows Expert Testimony Linking Johnson & Johnson Talc Products to Ovarian Cancer 
Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
Elon Musk Says Tesla Cybercab and Optimus Production Will Start Slowly Before Rapid Growth 
BHP Posts Record Iron Ore Output as China Pricing Pressures Loom 
Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
HKEX’s Permissive IPO Rules Could Open Opportunities for Korea to Strengthen Its Position in International Listings 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
Trump Criticizes NYSE Texas Expansion, Calls Dallas Exchange a Blow to New York 
Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
WALTHAM, Mass., April 27, 2017 -- Histogenics Corporation (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced it will release its financial and operational results for the quarter ended March 31, 2017, on May 11, 2017 before the market opens.
Histogenics’ management will host a conference call on Thursday, May 11, 2017 at 8:30 a.m. EDT. A question-and-answer session will follow Histogenics’ remarks. To participate on the live call, please dial (877) 930-8064 (domestic) or (253) 336-8040 (international) and provide the conference ID “97247103” five to ten minutes before the start of the call.
A live audio webcast of the presentation will be available via the “Investor Relations” page of the Histogenics website, www.histogenics.com. A replay of the webcast will be archived on Histogenics’ website for approximately 45 days following the presentation.
About Histogenics Corporation
Histogenics is a leading regenerative medicine company developing and commercializing products in the musculoskeletal segment of the marketplace. Histogenics’ regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions to treat musculoskeletal-related conditions. Histogenics’ first investigational product candidate, NeoCart®, is currently in Phase 3 clinical development. NeoCart is an autologous cell therapy designed to treat cartilage defects in the knee using the patient’s own cells. Knee cartilage defects represent a significant opportunity in the United States, with an estimated 500,000 or more applicable procedures each year. NeoCart is designed to exhibit characteristics of articular, hyaline cartilage prior to and upon implantation into the knee and therefore does not rely on the body to make new cartilage, characteristics not exhibited in other current treatment options. For more information, please visit www.histogenics.com.
Contact: Investor Relations Tel: +1 (781) 547-7909 [email protected]
